Executive Summary
This digest covers $541.8 million in civilian-only contract obligations from July 24, 2026, with zero defense-related awards, underscoring a pure civilian agency spending snapshot. The dominant theme is stable, long-duration health and infrastructure R&D, led by Leidos Biomedical Research's $173.3 million NIH vaccine trial contract—the highest-conviction bullish signal due to its cost-plus pricing and six-year revenue visibility.
However, three of four contracts are neutral, with two (PTSI Managed Services at NASA, Raytheon at FAA) nearing completion or representing immaterial revenue for large-cap RTX. Key risk: the $130.8 million PTSI NASA contract is fully executed, creating a revenue gap for that contractor absent follow-on awards.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Tracking the trend? Catch up on the prior Significant Contract Modifications ($10M+) digest from July 23, 2026.
Investment Signals (2)
- Leidos Biomedical Secures $173.3M NIH Vaccine Trial Contract with Low-Risk Pricing (HIGH)▲
Leidos Holdings subsidiary won a cost-plus-fixed-fee delivery order for Phase 1/2 vaccine trials through 2029, with $36.8M already funded, providing stable, low-volatility revenue.
- Frequentis USA Wins $124.6M FAA Delivery Order with High Funding Certainty (MEDIUM)▲
Time-and-materials contract for APC units at FAA shows $105.1M already outlayed (84% funded), indicating strong near-term cash flow for this foreign-owned manufacturer.
Risk Flags (2)
- Concentration [HIGH RISK]▼
PTSI Managed Services' $130.8M NASA contract is 78% paid and ended in 2023, creating a $19.3M annual revenue hole with no visible follow-on award in this dataset.
- Execution [LOW RISK]▼
Raytheon's $113.2M sole-source FAA contract is cost-plus, limiting margin upside, and represents only 0.16% of RTX's annual revenue, making it immaterial to earnings.
Opportunities (2)
- ◆
Leidos' NIH contract win under full competition signals potential for expanded health R&D awards as NIH vaccine funding remains stable through 2029.
- ◆
Raytheon's non-competed FAA STARS award confirms entrenched incumbent position, creating potential for follow-on sole-source modifications as FAA modernizes ground handling equipment.
Sector Themes (2)
- ◆
Three of four contracts (NASA, FAA, FAA) involve physical or telecom infrastructure, totaling $368.5M, indicating sustained civilian spending on facility and air traffic systems.
- ◆
Leidos' $173.3M NIH contract is the only bullish signal, with cost-plus pricing insulating margins from inflation and trial delays.
Watch List (3)
- 👁
{"entity" => "Leidos Holdings (LDOS)", "reason" => "Largest contract in digest ($173.3M) with 6-year revenue visibility; monitor trial outcome announcements for contract expansion.", "trigger" => "NIH Phase 1/2 trial milestone results or option exercises"}
- 👁
{"entity" => "PTSI Managed Services Inc", "reason" => "NASA contract fully executed; no new awards visible—risk of revenue cliff.", "trigger" => "New NASA GSFC facility contract award or modification"}
- 👁
{"entity" => "Frequentis USA, Inc", "reason" => "Foreign-owned contractor with $124.6M FAA award; regulatory risk if CFIUS scrutiny increases.", "trigger" => "FAA budget cycle for telecom equipment or regulatory policy changes"}
Get daily alerts with 2 investment signals, 2 risk alerts, 2 opportunities and full AI analysis of all 4 filings
$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: Significant Contract Modifications ($10M+)
🇺🇸 More from United States
View all →July 25, 2026
General Federal Contracts — July 25, 2026
General Federal Contracts
July 25, 2026
High-Value Federal Grants ($5M+) — July 25, 2026
High-Value Federal Grants ($5M+)
July 25, 2026
Mega Contracts Monitor ($100M+) — July 25, 2026
Mega Contracts Monitor ($100M+)
July 25, 2026
All HHS Contracts — July 25, 2026
All HHS Contracts